世界首款阿兹海默药被证明有效了！！！

希望 是真的！

Tech film上市公司的研发成果面向公众传播变成新闻时往往有misleading，Google lately的Quantities Superiority(量子优越性)同理，IBM首席架构官已经提出concern并指出这个术语的误导性了。地里的小伙伴还是有辨识力的高知群体哈，补充一点SEC(美国证监会)的information source.

百济神州(BioGene)Ltd is a biopharmaceutical company，主要从事用于治疗癌症的创新分子靶向及免疫oncology药物的developing, producing and saling Business. Multi-listed on NASDAQ: BGNE and HKEX:06160, BioGene is a 100% China-based company.
BioGene’s main products include Zanubrutinib(BGB-3111), Tislelizumab(BGB-A317) & Pamiparib(BGB-290), etc. 后两个产品即what this time press conference refers to，frankly speaking, at most just a 阶段性重大进展，don’t over-estimate it as an expert.

Attached is BioGene向SEC file 的ESMO Congress 2019 news report.
https://www.sec.gov/Archives/edg ... 0092/a8-kx10219.htm
https://www.sec.gov/Archives/edg ... esmodataenfinal.htm

'''
Have cover this stock since 2018. A little regret that didn't hold its stock till now.
'''

用码农的话解释就是，functional test test阶段过了（这里只是说早期阿氏症，可能也就front end部分test完了）， 看看integration test吧，同时申请一下FDA看能不能deploy一下，后面怎么着还不知道呢，离release版本还比较遥远

这是救世的好事

Biogen 几个月前 临床三期试验被证实无效

哗众取宠！
只不过是缓解症状。